Pibrentasvir

N/A

Report date: 2024/10/15 20:00:08
NME

Base Information

Drug NamePibrentasvir
Drug Alias Name哌仑他韦Pimodivirum2WU922TK3LABT-530A-1325912.0
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNonstructural protein 5A inhibitors
TargetsNonstructural protein 5A
Therapy Area/IndicationsFibrosisRenal InsufficiencyHepatic Insufficiency +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbvie Inc
Active IndicationsN/A
Inactive IndicationsFibrosisRenal InsufficiencyHepatic Insufficiency +[5] 

Other Information

ATC CodeN/A
Related LinksN/A